| ￥3300 | |
| Z05607-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 35.4 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 48-52 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized LRG1, His, Human, His Tag at 0.5 μg/ml(100 μl/well) on the plate. Dose response curve for Anti-LRG1 Antibody, hFc Tag with the EC50 of 5.2ng/ml determined by ELISA. »
The purity of LRG1, His, Human is greater than 95% as determined by SEC-HPLC. »
LRG1, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | Diabetic nephropathy (DN) is an important public health concern of increasing proportions and the leading cause of end-stage renal disease (ESRD) in diabetic patients. It is one of the most common long-term microvascular complications of diabetes mellitus that is characterized by proteinuria and glomerular structural changes. LRG1 is a novel pro-angiogenic factors involved in the abnormal angiogenesis and renal fibrosis in DN. |
| Synonyms | Leucine-rich alpha-2-glycoprotein; LRG;LRG1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
